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No established second-line chemotherapy is available for patients with advanced gastric cancer failing to respond or progressing to
first-line chemotherapy. However, 20–40% of these patients commonly receive second-line chemotherapy. We evaluated the
influence of clinico-pathologic factors on the survival of 175 advanced gastric cancer patients, who received second-line
chemotherapy at three oncology departments. Univariate and multivariate analyses found five factors which were independently
associated with poor overall survival: performance status 2 (hazard ratio (HR), 1.79; 95% CI, 1.16–2.77; P¼0.008), haemoglobin
p11.5gl
 1 (HR, 1.48; 95% CI, 1.06–2.05; P¼0.019), CEA level 450ngml
 1 (HR, 1.86; 95% CI, 1.21–2.88; P¼0.004), the
presence of greater than or equal to three metastatic sites of disease (HR, 1.72; 95% CI, 1.16–2.53; P¼0.006), and time-to-
progression under first-line chemotherapy p6 months (HR, 1.97; 95% CI, 1.39–2.80; Po0.0001). A prognostic index was
constructed dividing patients into low- (no risk factor), intermediate- (one to two risk factors), or high- (three to five risk factors) risk
groups, and median survival times for each group were 12.7 months, 7.1 months, and 3.3 months, respectively (Po0.001). In the
absence of data deriving from randomised trials, this analysis suggests that some easily available clinical factors may help to select
patients with advanced gastric cancer who could derive more benefit from second-line chemotherapy.
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Despite a declining incidence in many developed countries, gastric
cancer remains the second most common cause of cancer deaths,
and it is responsible for about 12% of all cancer-related deaths
worldwide (Parkin et al, 1999). As for most gastrointestinal
cancers, the management of gastric cancer is based on the surgical
resection of the primary tumour. However, more than two-thirds
of patients diagnosed with gastric cancer will have unresectable
disease (Parkin et al, 1999; Catalano et al, 2005; Macdonald, 2006),
and despite the fact that surgical pathological R0 resection can be
curative for many patients, recurrence rates are about 70% and
5-year survival rate is lower than 30% (Catalano et al, 2005). For
patients with unresectable disease, or developing recurrent disease
after curative resection, evidence supports the use of palliative
chemotherapy with the aims of improving symptoms, quality of
life, and possibly prolonging survival (Murad et al, 1993; Pyrhonen
et al, 1995; Glimelius et al, 1997). Several chemotherapy agents are
considered active in advanced gastric cancer. Over the past
decades, many anticancer drugs have been investigated, such as
5-fluorouracil (5-FU), cisplatin, anthracyclines, oral fluoropyrimi-
dines, irinotecan, oxaliplatin, and docetaxel (Catalano et al, 2005;
Dank et al, 2005; Al-Batran et al, 2006; Kang et al, 2006; Van
Cutsem et al, 2006; Cunningham et al, 2008). Combination
chemotherapy regimens have been developed in the hopes of
improving response rate and overall survival (OS). Unfortunately,
the benefits of combination chemotherapy have been modest
(Wagner et al, 2006). In general, regimens containing 5-FU and
cisplatin are widely accepted as potential standard therapies with a
response rate of 25–45% and median OS times of 7–9 months
(Ajani 2005; Catalano et al, 2005; Van Cutsem et al, 2006;
Cunningham et al, 2008). Although a large proportion of patients
with metastatic or recurrent gastric cancer may initially respond to
chemotherapy, they ultimately progress. In addition, many
patients have primary refractory disease. The median survival at
progression after first-line chemotherapy for metastatic gastric
cancer is about 2.5 months.
Yet, there is no established second-line chemotherapy for gastric
cancer, but it is used in 20–40% of patients (Chau et al, 2004a; Lee
et al, 2007). In three phase III randomised trials of 5-FU-based
first-line therapy enrolling a total of 1080 patients, 20% of them
went on to receive second-line chemotherapy, with a response rate
observed as 13.3% (95% CI, 6.8–22.5%), and a median survival
from starting second-line therapy of 5.6 months (Chau et al,
2004a).
During the past few decades, many phase II reports of second-
line therapy including gastric cancer patients have been published,
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sbut no randomised phase III trial investigating second-line
chemotherapy compared with best supportive care is available.
There is a great heterogeneity within each of phase II trial, partly
because of the variability in the responsiveness to first-line
chemotherapy, and the nature of previous chemotherapy (cispla-
tin-based or not). Morevover, available data have limitations
because of a publication bias; trials generally include small
numbers of participants and they do not support evidence for
identifying patients who are more likely to benefit from second-
line chemotherapy (Wilson et al, 2005).
A decision whether starting or not second-line chemo-
therapy for an individual patient may be a common clinical
scenario. Several factors should be considered: the potential
cumulative toxicity, especially for those patients with low
performance status (PS), the extent of disease, the need of
active drugs, the lack of cross-resistance to drugs previously used.
But second-line therapy could not be appropriate for all
patients, and prediction of treatment outcome may allow for the
identification of patients who would derive very little benefit
from second-line chemotherapy. The aim of this analysis was to
explore clinico-pathologic factors that may be associated with
survival of patients treated with second-line chemotherapy. In the
absence of definitive phase III trials, consideration of some of
these factors, if any, may assist in the selection of patients for
further treatment. However, as this analysis was performed on
patients receiving cytotoxic drugs, it is not possible to extrapolate
results for patients treated with novel biological agents and
within clinical trials.
PATIENTS AND METHODS
From January 1995 to August 2006, 625 patients received first-line
chemotherapy at three oncology departments (San Salvatore
Hospital, Pesaro; Hospital of Urbino; Campus Biomedico, Rome).
Of them, 175 (28%) consecutive patients received second-line
chemotherapy for locally advanced or metastatic gastric cancer. No
patient receiving second-line chemotherapy was excluded from
this analysis. The criteria for case inclusion were as follows:
(i) histologically confirmed diagnosis of gastric cancer;
(ii) previous treatment with first-line chemotherapy, given until
disease progression, unacceptable toxicity, or patient’s refusal;
(iii) presence of measurable disease; (iv) progressing disease after
the first-line chemotherapy; (v) availability of clinico-pathological
data at the beginning of second-line chemotherapy.
Approval of the study was obtained from the local research and
ethics committee.
The clinical tumour response was assessed according to
Response Evaluation Criteria in Solid Tumors (RECIST) (Therasse
et al, 2000).
Factors included in the univariate analyses were as follows: age,
sex, PS, loss of weight 45%; haemoglobin, serum albumin, CEA
levels; previous gastrectomy, Lauren classification, tumour grade,
tumour location, metastasis to liver, peritoneum, number of
metastatic sites; time-to-progression (TTP), objective response to
first-line chemotherapy, regimen used as first-line chemotherapy
(oxaliplatin or cisplatin plus 5-FU-based vs 5-FU-based). Labora-
tory variables were initially recorded as continuous variables and
later dichotomised according to the median value of each variable.
Performance status was evaluated according to the Eastern
Cooperative Oncology Group (ECOG) criteria. Time-to-progres-
sion under first-line chemotherapy was measured from the date of
the beginning of the treatment to the date of progression. To refine
its possible association with survival to second-line chemotherapy,
TTP under first-line chemotherapy was studied dichotomising the
study population according to disease progression less than or
equal to the median TTP vs disease progression greater than the
median TTP.
Statistical analysis
This is a multicentric, retrospective study. The primary end point of
the study was OS. Overall survival was measured from the date of
the first cycle of second-line chemotherapy to the date of death or
the last follow-up visit. Survival data were analysed using the
Kaplan–Meier product-limit method (Kaplan and Meier, 1958).
Comparison of survival curves were performed using log-rank test
(Peto and Peto, 1972). A prognostic model was established by
searching all variables that significantly influenced OS at a level of P-
values o0.05 in the univariate analysis. Multivariate analysis was
carried out using stepwise Cox proportional hazards regression
modelling. P-values o0.05 were considered statistically significant
and all P-values correspond to two-sided significance tests.
RESULTS
The characteristics of patients included in this analysis are shown
in Table 1. The median age was 64 years with a range of 38–83
years. Sixty-six percent of patients were male, and 23.4% had
Table 1 Patient characteristics at baseline (n¼175)
Characteristics No. of patients
Age (median age, range) 64 (38–83)
Male/female 116/59
Previous gastrectomy
Performance status (ECOG)
0/1/2 53/76/41
Disease status
Locally advanced/metastatic 4/171
Site of primary tumour
GEJ/cardia 28
Body 66
Antrum 63
Anastomosis 9
Multiple sites 9
Previous gastrectomy
Yes/no 136/49
Histology
Adenocarcinoma 139
Signet ring cell carcinoma 27
Undifferentiated 9
Grade
Well/moderately/poorly differentiated 5/41/102
Not known 27
Lauren classification
Intestinal/diffuse 105/70
Haemoglobin, gl
 1 (median, range) 11.5 (7.3–15.6)
Albumin, g per 100ml (median, range) 3.5 (1.8–4.9)
CEA, ngml
 1(median, range) 50 (1 to 4500)
Sites of disease
Stomach/local relapse 77
Liver 66
Peritoneum 80
Lymph node 69
Number of metastatic sites
1–2 125
3–4 50
ECOG¼Eastern Cooperative Oncology Group; GEJ¼gastroesophageal junction.
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77.7% of patients received previous gastrectomy.
Treatment
First-line chemotherapy contained 5-FU (n¼13), 5-FU and
cisplatin (n¼141), or 5-FU and oxaliplatin (n¼21) (Table 2).
Twelve patients (6.8%) experienced a complete response, and 71
patients (40.6%) a partial response for an overall response rate of
47.4% (95% CI, 40.0–54.8). Median TTP under first-line
chemotherapy was 6 months (range, 1–68 months).
All the patients received 5-FU as second-line chemotherapy,
given as bolus i.v. or continuous infusion and combined with other
drugs. Second-line chemotherapy consisted of regimens contain-
ing 5-FU and cisplatin (n¼21), 5-FU and oxaliplatin (n¼31),
5-FU and irinotecan (n¼51), 5-FU and paclitaxel or docetaxel
(n¼25), and 5-FU-based (n¼47). In any case, no combination of
drugs received as first-line treatment was subsequently given at
disease progression. A complete response to second-line chemo-
therapy was achieved in 3 patients and a partial response in 25
patients, for an overall response rate of 16.0% (95% CI, 10.6–21.4).
Univariate and multivariate analysis
At the time of analysis, 163 (93.1%) patients had died from tumour
progression. Median survival for the whole group was 6.1 months,
and 1-year OS was 20.5% (95% CI, 14.4–26.6) (Figure 1).
At univariate analysis (Table 3), eight variables were signifi-
cantly associated with poor survival time: ECOG PS 2, loss of
weight 45%, haemoglobin p11.5gl
 1, CEA 450ngml
 1, the
presence of peritoneal carcinomatosis, a number of metastatic sites
3–4, TTP under first-line chemotherapy p6 months, and previous
chemotherapy with regimens containing 5-FU alone. No statisti-
cally significative difference was found between each regimen used
as second-line chemotherapy.
Multivariate regression analysis (Table 4) included the eight
variables that were found to have prognostic significance in
univariate analysis. These features were available for all 175
patients. Five factors, PS, haemoglobin, CEA, the number of
metastatic sites, and TTP under first-line chemotherapy, showed
independent prognostic role.
The multivariate analysis was also performed by stratificating
for the second-line chemotherapy received. However, we found no
interaction between any second-line treatment and each clinico-
pathologic variable (data not shown).
Then, a multivariate prognostic model was constructed by
incorporating all the five adverse prognostic factors. The prog-
nostic grouping was carried out according to the following criteria:
low-risk group, patients with no prognostic factor (n¼25);
intermediate-risk group, patients with one or two negative
prognostic factors (n¼101); high-risk group, patients with three
to five negative prognostic factors (n¼49). The survival curves
according to the prognostic model are shown in Figure 2. Median
survival times for low-, intermediate-, and high-risk groups were
12.7, 7.1, and 3.3 months, respectively. One-year survival rates for
each group were 59.5% (95% CI, 39.0–79.9), 21.1% (95% CI, 12.7–
29.5), and 4.6% (95% CI, 0–10.8), respectively. There were marked
significant survival differences among the three risk groups
(Po0.001).
When compared to the low-risk group, the intermediate-risk
group had a two-fold (HR, 2.18; 95% CI, 1.38–3.30), and the high-
risk group had a 3.5-fold (HR, 3.61; 95% CI, 3.4–11.67) increased
risk of death.
DISCUSSION
Despite new schedules and association of drugs, patients with
advanced gastric cancer treated with first-line chemotherapy have
median OS rarely approaching 11 months (Catalano et al, 2005;
Dank et al, 2005; Al-Batran et al, 2006; Kang et al 2006; Van
Cutsem et al, 2006; Cunningham et al, 2008). No significant steps
ahead have been moved since the past decade. Many patients did
not respond to first-line chemotherapy or have progression of
their disease within some months from the end of treatment.
Table 2 Results of first-line and second-line chemotherapy (n¼175)
No. of patients
First-line chemotherapy
Treatment
5-FU-based 13
5FU/cisplatin-based 141
5-FU/oxaliplatin-based 21
Response rate
CR 12
PR 71
ORR 47.4% (95% CI, 40.0–54.8)
SD 48
PD 44
TTP, median (range) 6 months (1–68)
Second-line chemotherapy
Treatment
5-FU-based 47
5-FU/CDDP-based 21
5-FU/oxaliplatin-based 31
5-FU/irinotecan-based 51
5-FU/taxane 25
Response rate
CR 3
PR 25
ORR 16.0% (95% CI, 10.6–21.4)
SD 59
PD 88
5-FU¼5-fluorouracil; CI¼confidence interval; CR¼complete response;
ORR¼overall response rate (according to RECIST); PD¼progressive disease;
PR¼partial response; SD¼stable disease; Taxane¼docetaxel, paclitaxel;
TTP¼time-to-progression.
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Figure 1 Overall survival curve for the whole group (n¼175).
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effective first-line regimens are necessary. No established second-
line therapy is available and decision whether to treat or not such
patients with second-line chemotherapy is crucial.
This analysis based on the individual data of 175 consecutive
patients treated with second-line chemotherapy identifies five
independent prognostic factors: PS, haemoglobin level, CEA level,
number of metastatic sites, TTP under first-line chemotherapy. To
our knowledge, this is the first report, which assess pre-treatment
clinical prognostic factors for patients receiving second-line
therapy for advanced gastric cancer. Conversely, three different
studies (Yoshida et al, 2004; Chau et al, 2004b; Lee et al, 2007)
aimed to identify clinical prognostic factors for metastatic gastric
cancer patients undergoing first-line chemotherapy. Chau et al
(2004b) assessed prognostic factors on 1080 patients with locally
advanced and metastatic oesophago-gastric cancer. Four indepen-
dent poor prognostic factors were identified by multivariate
analysis: PS X2, liver metastases, peritoneal metastases, and alkaline
phosphatase X100Ul
 1. A prognostic index was developed dividing
patients into good (no risk factor), moderate (one to two risk
factors) or poor (three to four risk factors) risk groups. One-year
survival for good, moderate, and poor risk groups were 48.5, 25.7,
and 11%, respectively, with a highly significant difference among
the three groups (Po0.0001). In the second study (Yoshida et al,
2004), the Japan Clinical Oncology Group (JCOG) showed that
better PS, a limited number of metastatic sites, and macroscopi-
cally scirrhous type tumours were significantly associated with
poor survival in metastatic gastric cancer patients.
Recently, Lee et al (2007) published a multivariate analysis on
1445 gastric cancer patients undergoing first-line chemotherapy.
Table 3 Univariate analysis (n¼175)
Variable MST (months) 1-year survival (%) P-value
Age
p64 6.0 23.2 0.396
464 6.0 18.2
Sex
Male 6.3 18.7 0.967
Female 5.8 24.6
Performance status (ECOG)
0–1 7.5 25.3 o0.001
2 2.5 8.1
Loss of weight 45%
Yes 5.0 14.7 0.003
No 7.5 24.3
Haemoglobin
p11.5gl
 1 5.0 14.2 0.002
411.5gl
 1 7.8 28.8
Albumin
p3.5g per 100ml 5.5 19.5 0.08
43.5g per 100ml 6.8 26.7
CEA
p50ngml
 1 7.0 25.2 0.002
450ngml
 1 5.0 3.8
Previous gastrectomy
Yes 6.6 21.7 0.23
No 4.1 16.6
Lauren classification
Intestinal 6.5 19.4 0.791
Diffuse 5.5 22.2
Grade
Well to moderate 6.5 18.4 0.447
Poor 6.2 22.2
Site of primary
GEJ to cardia 6.5 25.4 0.365
Body to antrum 6.0 19.7
Liver metastasis
Yes 5.5 13.9 0.194
No 6.6 24.8
Peritoneal metastasis
Yes 5.0 14.6 0.005
No 7.3 25.5
Number of metastatic sites
1–2 7.2 26.2 o0.001
3–4 3.8 6.2
First-line chemotherapy
5-FU-based 4.5 0.0 0.021
5FU/platinum-based 6.1 19.1
Response to first-line chemotherapy
Yes 7.0 24.3 0.297
No 5.5 16.6
TTP of first-line chemotherapyp6m o s
Yes 4.8 9.1 o0.001
No 11.0 36.6
Year
1995–2000 5.5 3.8 0.128
2001–2006 7.2 4.9
5-FU¼5-fluorouracil; ECOG¼Eastern Cooperative Oncology Group; GEJ¼
gastroesophageal junction; mos¼months; MST¼median survival time;
Platinum¼cisplatin, ovaliplatin; TTP¼time-to-progression.
Table 4 Multivariate analysis (n¼175)
Variable HR 95% CI P-value
ECOG performance status 2 1.79 1.16–2.77 0.008
Loss of weight 45% 1.05 0.73–1.53 0.77
Haemoglobin p11.5gl
 1 1.48 1.06–2.05 0.019
CEA450ngml
 1 1.86 1.21–2.88 0.004
Peritoneal metastasis 1.16 0.80–1.68 0.41
Number of metastatic sites 3–4 1.72 1.16–2.53 0.006
5-FU-based first-line chemotherapy 1.97 0.86–3.74 0.0733
TTP of the first-line chemotherapy p6 months 1.97 1.39–2.80 o0.0001
5-FU¼5-fluorouracil; CI¼confidence interval; ECOG¼Eastern Cooperative
Oncology Group; HR¼hazard ratio; TTP¼time-to-progression.
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Figure 2 Survival curves according to the risk groups. Marks on survival
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phosphatase 485Ul
 1,P S X2, bone metastases, and ascites were
the main clinical parameters associated with poor survival. The
authors used these factors to develop a prognostic model to predict
survival by categorising patients into three risk groups: low,
intermediate, and high, with corresponding median survival times
of 12.5, 7, 2.7 months, respectively (Po0.001).
Even if no effective second-line chemotherapy has been
established yet, in this setting several phase II trials were published
during the last decades (Scho ¨ffski 2002; Wilson et al, 2005; Sastre
et al, 2006). These studies suggest response rates similar to those
achieved in other cancers, such as colorectal, lung, ovarian cancers
(Scho ¨ffski 2002; Colombo et al, 2006; Goldberg et al, 2007;
Vansteenkiste, 2007). However, we still lack of phase III trials
comparing second-line chemotherapy vs best supportive care.
In this report, we used the independent prognostic factors to
define three different risk groups of patients, low-risk group,
patients with no prognostic factor; intermediate-risk group,
patients with one or two negative prognostic factors; high-risk
group, patients with three to five negative prognostic factors, with
median survival time of 12.7, 7.1, and 3.3 months, respectively. The
benefit of each risk group is quite similar to that reported in the
other series including patients treated with first-line chemotherapy
(Chau et al, 2004b; Lee et al, 2007). Therefore, it is plausible that
patients with no or a limited number of poor prognostic factors
may derive the same benefit from second-line chemotherapy as
patients treated with first-line chemotherapy.
This analysis confirms the importance of PS when receiving
second-line treatment (Yoshida et al, 2004; Chau et al, 2004b; Lee
et al, 2007). As general conditions of patients with advanced
gastric cancer may rapidly deteriorate after first-line chemother-
apy, second-line therapy should be limited to patients with good
PS. Moreover, consideration of good PS is of high importance not
only as it is associated with OS, but also when we consider
tolerability of chemotherapy.
Park et al (2006) suggested that low baseline haemoglobin level
(o10gl
 1) is a strong and independent prognostic factor for the
outcomes of advanced gastric cancer patients receiving 5-FU-based
first-line chemotherapy. Similarly, in our analysis, haemoglobin
level was found of prognostic value after uni- and multivariate
analysis, while conflicting results were emphasised in other reports
considering the presence of anaemia at onset of first-line
chemotherapy (Chau et al, 2004b; Lee et al, 2007).
Serum CEA level is a common preoperative and follow-up marker
of gastrointestinal tumours (Holyoke et al, 1975; Korenaga et al,
1995). Serum CEA is a useful indicator of potential curability in
patients who undergo gastrectomy and it provides predictive value
in determining tumour stage and prognostic information for patients
with potentially resectable gastric cancer (Ikeda et al, 1995;
Tachibana et al, 1998; Kochi et al, 2000). Increased CEA was found
to be univariate adverse prognostic factor for survival in locally
advanced or metastatic gastric cancer patients treated with first-line
chemotherapy (Louvet et al, 2003). In our series, CEA 450ngml
 1
was a negative prognostic factor and this may reflect the metastatic
potential of malignant cells (Hostetter et al, 1990).
The presence of peritoneal metastases or ascites are poor
independent prognostic factors for gastric cancer patients receiving
first-line chemotherapy (Chau et al, 2004b; Lee et al, 2007).
In the present analysis, peritoneal metastasis had some prognostic
value at the univariate analysis, but the multivariate analysis failed
to show any independent prognostic significance. We cannot rule
out a possible interaction of peritoneal disease with other factors,
such as PS, number of metastatic sites, or TTP under first-line
chemotherapy. Patients with clinically or radiologically gross
peritoneal metastases also more frequently have lower PS, poor
tumour response to chemotherapy and survival than patients with
small amount of peritoneal disease or diagnosed at explorative
laparotomy (Sadeghi et al, 2000; Chau et al, 2004b). Number of
metastatic sites of disease was significantly associated with OS, and
this confirms what was previously reported in gastrointestinal
cancers (Mitry et al, 2004; Yoshida et al, 2004).
In a small report, TTP under first-line treatment has been
suggested as useful selection criteria for second-line chemotherapy
(Stahl et al, 2005). It was a predictor for patients (n¼27) who did
benefit from the second-line chemotherapy with a median survival
from the start of second-line therapy of 10.6 months, compared to
5.1 months for the overall group. For this reason, in our analysis
we explored the possible prognostic role of TTP under first-line
chemotherapy. Patients with TTP under first-line chemotherapy
p6 months and treated with second-line chemotherapy had a
median survival time since the starting date of the second-line
therapy of 11 months, which represents the best median OS of
active first-line triple-agents regimens for metastatic gastric cancer
(Wagner et al, 2006). Then, patients with rapidly progressing
disease are an unfavourable setting of patients more unlikely to
take advantage from second-line chemotherapy.
The present analysis has been performed in patients receiving
second-line chemotherapy and it cannot account for novel biologic
agents. Therefore, any conclusion cannot be generalised for the
treatments including cytotoxic drugs and biologic agents. Clinico-
pathologic and tumour biologic factors may help to find optimal
candidates for additional therapy with targeted agents and
cytotoxic drugs, also in the context of clinical trials. This strategy
may be crucial to develop new approaches for this lethal disease.
Moreover, patients with high-risk factors should be refrained from
fruitless cytotoxic therapy, and this group of patients may be the
one that should be candidate for non-cytotoxic treatments.
In conclusion, in the absence of a standard regimen, this
analysis suggests that some clinical factors, which are easily
identifiable, may define some groups of patients with gastric
cancer more likely to benefit from a second-line chemotherapy.
Phase III randomised trials comparing second-line chemotherapy
vs best supportive care in patients with advanced gastric cancer are
highly warranted. However, we also need to evaluate new agents
including the targeted agents for this population incorporating
prognostic and predictive markers as a component of trial design.
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